kyowa Kirin

Update in progress

4151.T (Tokyo)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Kyowa Kirin is a global pharmaceutical company that conducts research, development, manufacturing, and marketing of medicines. It markets Ziftomenib for adult relapsed/refractory AML with NPM1 mutation and Lumicef for palmoplantar pustulosis. It also has multiple active programs (Phase I–III) including rocatinlimab, infigratinib, OTL-203, OTL-201, and several KK assets for various diseases. It collaborates with La Jolla Institute, AstraZeneca, and Amgen. Based in Chiyoda, Tokyo, and a Kirin Holdings subsidiary. Formerly Kyowa Hakko Kirin; renamed in 2019.

Company score

Sentiment: 0.23; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.03; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.16; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.14; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive